{"id":1629,"date":"2023-05-17T07:00:00","date_gmt":"2023-05-17T05:00:00","guid":{"rendered":"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-to-present-new-bylvay-odevixibat-data-at-annual-espghan-congress-showcasing-commitment-to-furthering-treatment-for-rare-cholestatic-liver-diseases\/"},"modified":"2023-05-23T14:11:13","modified_gmt":"2023-05-23T14:11:13","slug":"ipsen-to-present-new-bylvay-odevixibat-data-at-annual-espghan-congress-showcasing-commitment-to-furthering-treatment-for-rare-cholestatic-liver-diseases","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-to-present-new-bylvay-odevixibat-data-at-annual-espghan-congress-showcasing-commitment-to-furthering-treatment-for-rare-cholestatic-liver-diseases\/","title":{"rendered":"Ipsen to present new Bylvay\u00ae (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases"},"content":{"rendered":"<p align=\"justify\"><strong>PARIS, FRANCE,<\/strong> <strong>1<\/strong><strong>7<\/strong> <strong>May 2023<\/strong> \u2013 Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new data from its growing rare disease portfolio will be presented at the 55th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN), taking place in Vienna, Austria 17-20 May 2023. The six data presentations, made up of four oral, one poster, and one e-poster, consistently demonstrate the efficacy and tolerability of investigational Bylvay\u00ae (odevixibat) for the potential treatment of cholestatic liver disease patients with Alagille syndrome (ALGS) and the treatment of patients with progressive familial intrahepatic cholestasis (PFIC).<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[],"tags":[],"class_list":["post-1629","press_release","type-press_release","status-publish","hentry","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ipsen to present new Bylvay\u00ae (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases - Annual Report<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-to-present-new-bylvay-odevixibat-data-at-annual-espghan-congress-showcasing-commitment-to-furthering-treatment-for-rare-cholestatic-liver-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen to present new Bylvay\u00ae (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases - Annual Report\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-to-present-new-bylvay-odevixibat-data-at-annual-espghan-congress-showcasing-commitment-to-furthering-treatment-for-rare-cholestatic-liver-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Annual Report\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-23T14:11:13+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-to-present-new-bylvay-odevixibat-data-at-annual-espghan-congress-showcasing-commitment-to-furthering-treatment-for-rare-cholestatic-liver-diseases\/\",\"url\":\"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-to-present-new-bylvay-odevixibat-data-at-annual-espghan-congress-showcasing-commitment-to-furthering-treatment-for-rare-cholestatic-liver-diseases\/\",\"name\":\"Ipsen to present new Bylvay\u00ae (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases - Annual Report\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#website\"},\"datePublished\":\"2023-05-17T05:00:00+00:00\",\"dateModified\":\"2023-05-23T14:11:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-to-present-new-bylvay-odevixibat-data-at-annual-espghan-congress-showcasing-commitment-to-furthering-treatment-for-rare-cholestatic-liver-diseases\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-to-present-new-bylvay-odevixibat-data-at-annual-espghan-congress-showcasing-commitment-to-furthering-treatment-for-rare-cholestatic-liver-diseases\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-to-present-new-bylvay-odevixibat-data-at-annual-espghan-congress-showcasing-commitment-to-furthering-treatment-for-rare-cholestatic-liver-diseases\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/annualreport\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen to present new Bylvay\u00ae (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#website\",\"url\":\"https:\/\/www.ipsen.com\/annualreport\/\",\"name\":\"Annual Report\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/annualreport\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#organization\",\"name\":\"Annual Report\",\"url\":\"https:\/\/www.ipsen.com\/annualreport\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/annualreport\/wp-content\/uploads\/sites\/3\/2023\/12\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/annualreport\/wp-content\/uploads\/sites\/3\/2023\/12\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"Annual Report\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen to present new Bylvay\u00ae (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases - Annual Report","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-to-present-new-bylvay-odevixibat-data-at-annual-espghan-congress-showcasing-commitment-to-furthering-treatment-for-rare-cholestatic-liver-diseases\/","og_locale":"en_US","og_type":"article","og_title":"Ipsen to present new Bylvay\u00ae (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases - Annual Report","og_url":"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-to-present-new-bylvay-odevixibat-data-at-annual-espghan-congress-showcasing-commitment-to-furthering-treatment-for-rare-cholestatic-liver-diseases\/","og_site_name":"Annual Report","article_modified_time":"2023-05-23T14:11:13+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-to-present-new-bylvay-odevixibat-data-at-annual-espghan-congress-showcasing-commitment-to-furthering-treatment-for-rare-cholestatic-liver-diseases\/","url":"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-to-present-new-bylvay-odevixibat-data-at-annual-espghan-congress-showcasing-commitment-to-furthering-treatment-for-rare-cholestatic-liver-diseases\/","name":"Ipsen to present new Bylvay\u00ae (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases - Annual Report","isPartOf":{"@id":"https:\/\/www.ipsen.com\/annualreport\/#website"},"datePublished":"2023-05-17T05:00:00+00:00","dateModified":"2023-05-23T14:11:13+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-to-present-new-bylvay-odevixibat-data-at-annual-espghan-congress-showcasing-commitment-to-furthering-treatment-for-rare-cholestatic-liver-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-to-present-new-bylvay-odevixibat-data-at-annual-espghan-congress-showcasing-commitment-to-furthering-treatment-for-rare-cholestatic-liver-diseases\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-to-present-new-bylvay-odevixibat-data-at-annual-espghan-congress-showcasing-commitment-to-furthering-treatment-for-rare-cholestatic-liver-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/annualreport\/"},{"@type":"ListItem","position":2,"name":"Ipsen to present new Bylvay\u00ae (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/annualreport\/#website","url":"https:\/\/www.ipsen.com\/annualreport\/","name":"Annual Report","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/annualreport\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/annualreport\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/annualreport\/#organization","name":"Annual Report","url":"https:\/\/www.ipsen.com\/annualreport\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ipsen.com\/annualreport\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/annualreport\/wp-content\/uploads\/sites\/3\/2023\/12\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/annualreport\/wp-content\/uploads\/sites\/3\/2023\/12\/Latest_Ipsen-logo_168x48.svg","caption":"Annual Report"},"image":{"@id":"https:\/\/www.ipsen.com\/annualreport\/#\/schema\/logo\/image\/"}}]}},"parsely":{"version":"1.1.0","canonical_url":"https:\/\/ipsen.com\/annualreport\/press-releases\/ipsen-to-present-new-bylvay-odevixibat-data-at-annual-espghan-congress-showcasing-commitment-to-furthering-treatment-for-rare-cholestatic-liver-diseases\/","smart_links":{"inbound":0,"outbound":0},"traffic_boost_suggestions_count":0,"meta":{"@context":"https:\/\/schema.org","@type":"NewsArticle","headline":"Ipsen to present new Bylvay\u00ae (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases","url":"http:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-to-present-new-bylvay-odevixibat-data-at-annual-espghan-congress-showcasing-commitment-to-furthering-treatment-for-rare-cholestatic-liver-diseases\/","mainEntityOfPage":{"@type":"WebPage","@id":"http:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-to-present-new-bylvay-odevixibat-data-at-annual-espghan-congress-showcasing-commitment-to-furthering-treatment-for-rare-cholestatic-liver-diseases\/"},"thumbnailUrl":"","image":{"@type":"ImageObject","url":""},"articleSection":"Gereral","author":[{"@type":"Person","name":"IPSEN"}],"creator":["IPSEN"],"publisher":{"@type":"Organization","name":"Annual Report","logo":""},"keywords":[],"dateCreated":"2023-05-17T05:00:00Z","datePublished":"2023-05-17T05:00:00Z","dateModified":"2023-05-23T14:11:13Z"},"rendered":"<script type=\"application\/ld+json\" class=\"wp-parsely-metadata\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@type\":\"NewsArticle\",\"headline\":\"Ipsen to present new Bylvay\\u00ae (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases\",\"url\":\"http:\\\/\\\/www.ipsen.com\\\/annualreport\\\/press-releases\\\/ipsen-to-present-new-bylvay-odevixibat-data-at-annual-espghan-congress-showcasing-commitment-to-furthering-treatment-for-rare-cholestatic-liver-diseases\\\/\",\"mainEntityOfPage\":{\"@type\":\"WebPage\",\"@id\":\"http:\\\/\\\/www.ipsen.com\\\/annualreport\\\/press-releases\\\/ipsen-to-present-new-bylvay-odevixibat-data-at-annual-espghan-congress-showcasing-commitment-to-furthering-treatment-for-rare-cholestatic-liver-diseases\\\/\"},\"thumbnailUrl\":\"\",\"image\":{\"@type\":\"ImageObject\",\"url\":\"\"},\"articleSection\":\"Gereral\",\"author\":[{\"@type\":\"Person\",\"name\":\"IPSEN\"}],\"creator\":[\"IPSEN\"],\"publisher\":{\"@type\":\"Organization\",\"name\":\"Annual Report\",\"logo\":\"\"},\"keywords\":[],\"dateCreated\":\"2023-05-17T05:00:00Z\",\"datePublished\":\"2023-05-17T05:00:00Z\",\"dateModified\":\"2023-05-23T14:11:13Z\"}<\/script>","tracker_url":"https:\/\/cdn.parsely.com\/keys\/ipsen.com\/p.js"},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/annualreport\/wp-json\/wp\/v2\/press_release\/1629","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/annualreport\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/annualreport\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/annualreport\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":0,"href":"https:\/\/www.ipsen.com\/annualreport\/wp-json\/wp\/v2\/press_release\/1629\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/annualreport\/wp-json\/wp\/v2\/media?parent=1629"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/annualreport\/wp-json\/wp\/v2\/categories?post=1629"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/annualreport\/wp-json\/wp\/v2\/tags?post=1629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}